Skip to main content
Livermore
Livermore
ZHEN

Deep Track Capital, LP

SEC CIK
0001856083
Latest filing
Aug 14, 2026

The latest 13F from Deep Track Capital, LP covers Q2 2026 (filed Aug 14, 2026): 66 long positions worth $6.79B. The top 10 holdings make up 40.1% of the portfolio, and the largest is Guardant Health, Inc. (GH) at 7.5%. Livermore has 20 filings on Form 13F from this institution, going back to Q4 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
18
Est. +$944.5M
Added
22
Est. +$771.1M
Reduced
15
Est. −$415.8M
Sold out
14
Est. −$652.0M

Top 5 holdings

Share of this quarter's portfolio value

  1. GHGuardant Health, Inc.
    7.5%$509.1MHistory
  2. IMVTImmunovant, Inc.
    5.3%$359.9MHistory
  3. GPCRStructure Therapeutics Inc.
    3.7%$254.4MHistory
  4. PCVXVaxcyte, Inc.
    3.7%$250.0MHistory
  5. ALNYAlnylam Pharmaceuticals, Inc.
    3.7%$248.3MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. ALNYAlnylam Pharmaceuticals, Inc.
    +$248.3MNewHistory
  2. MANEVeradermics, Inc
    +$184.4MAddedHistory
  3. COAGHemab Therapeutics Holdings, Inc.
    +$132.3MNewHistory
  4. BMRNBiomarin Pharmaceutical Inc
    +$123.5MAddedHistory
  5. GHRSGH Research PLC
    +$89.6MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. ALNYAlnylam Pharmaceuticals, Inc.
    +3.66 pp0.0% → 3.7%History
  2. MANEVeradermics, Inc
    +2.97 pp0.7% → 3.6%History
  3. COAGHemab Therapeutics Holdings, Inc.
    +1.95 pp0.0% → 1.9%History
  4. BMRNBiomarin Pharmaceutical Inc
    +1.45 pp1.3% → 2.8%History
  5. GHRSGH Research PLC
    +1.32 pp0.0% → 1.3%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. APLSApellis Pharmaceuticals, Inc.
    −$182.3MSold outHistory
  2. CNTACentessa Pharmaceuticals plc
    −$125.4MSold outHistory
  3. AXSMAxsome Therapeutics, Inc.
    −$97.9MReducedHistory
  4. IMVTImmunovant, Inc.
    −$84.2MReducedHistory
  5. BBIOBridgeBio Pharma, Inc.
    −$62.5MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. APLSApellis Pharmaceuticals, Inc.
    −3.76 pp3.8% → 0.0%History
  2. CNTACentessa Pharmaceuticals plc
    −2.59 pp2.6% → 0.0%History
  3. AXSMAxsome Therapeutics, Inc.
    −1.31 pp3.8% → 2.5%History
  4. BBIOBridgeBio Pharma, Inc.
    −1.29 pp1.3% → 0.0%History
  5. TERNTerns Pharmaceuticals, Inc.
    −1.17 pp1.2% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$6.79B
+$1.94B (+40.1%) vs. prior quarter
Positions
66
+4 vs. prior quarter
Top 10 concentration
40.1%
Top 10 as share of value
Turnover
18.4%
Q2 2026, one quarter
Average holding period
6.5 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2021), so positions held before then are understated.

13F filings by quarter

19 quarters, going back to Q4 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $6.79B (Q2 2026)

Q4 2021: $1.35BQ1 2022: $1.55BQ2 2022: $1.45BQ3 2022: $2.02BQ4 2022: $2.29BQ1 2023: $2.35BQ2 2023: $2.14BQ3 2023: $2.58BQ4 2023: $2.85BQ1 2024: $3.48BQ2 2024: $3.35BQ3 2024: $3.13BQ4 2024: $2.67BQ1 2025: $3.09BQ2 2025: $3.11BQ3 2025: $3.58BQ4 2025: $4.38BQ1 2026: $4.85BQ2 2026: $6.79B
Q4 2021Q2 2026
13F filings of Deep Track Capital, LP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202666$6.79BGHIMVTGPCRvs. Q1 2026SEC
Q1 2026May 15, 202662$4.85BGHIMVTTARSvs. Q4 2025SEC
Q4 2025Feb 13, 202653$4.38BIMVTGHGPCRvs. Q3 2025SEC
Q3 2025Nov 14, 202556$3.58BGHIONSCYTKvs. Q2 2025SEC
Q2 2025Aug 14, 202565$3.11BGHIONSPTGXvs. Q1 2025SEC
Q1 2025May 15, 202569$3.09BITCIGHDVAXvs. Q4 2024SEC
Q4 2024Feb 14, 202561$2.67BDVAXGHITCIvs. Q3 2024SEC
Q3 2024Nov 14, 202469$3.13BARGXDVAXGHvs. Q2 2024SEC
Q2 2024Aug 14, 202467$3.35BAMGNARGXAXSMvs. Q1 2024SEC
Q1 2024May 15, 202465$3.48BSWTXAMGNAPGEvs. Q4 2023SEC
Q4 2023Feb 14, 202457$2.85BINSMSWTXITCIvs. Q3 2023SEC
Q3 2023Nov 14, 202362$2.58BINSMJAZZITCIvs. Q2 2023SEC
Q2 2023Sep 6, 2023Amended53$2.14BJAZZINSMIONSvs. Q1 2023SEC
Q1 2023May 15, 202354$2.35BJAZZISEETVTXvs. Q4 2022SEC
Q4 2022Feb 14, 202357$2.29BIMVTISEEJAZZvs. Q3 2022SEC
Q3 2022Nov 14, 202260$2.02BISEEJAZZTVTXvs. Q2 2022SEC
Q2 2022Aug 12, 202249$1.45BGBTNVCRTVTXvs. Q1 2022SEC
Q1 2022May 16, 202249$1.55BNVCRBCYCTVTXvs. Q4 2021SEC
Q4 2021Feb 14, 202249$1.35BKROSTVTXBCYC–SEC

13D and 13G filings

Companies where Deep Track Capital, LP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

27 companies, largest stake first.

Companies where Deep Track Capital, LP owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
LBRXLB Pharmaceuticals Inc13D/A11.70%3.35M shares−3.20 ppfrom 14.90%Sep 19, 20252 filingsFeb 10, 2026SEC
ALTAltimmune, Inc.13G9.99%19.4M sharesNewApr 30, 20261 filingApr 30, 2026SEC
CMPSCOMPASS Pathways plc13G9.99%9.27M sharesNewJan 17, 20251 filingJan 17, 2025SEC
VSTMVerastem, Inc.13G9.99%7.72M sharesNewNov 21, 20251 filingNov 21, 2025SEC
PMNProMIS Neurosciences Inc.13G9.99%902.6K sharesNewFeb 6, 20261 filingFeb 6, 2026SEC
MLTXMoonLake Immunotherapeutics13G/A9.74%8.00M shares+3.28 ppfrom 6.46%Nov 12, 20252 filingsAug 14, 2026SEC
OCULOcular Therapeutix, Inc13G/A9.53%20.9M shares+4.40 ppfrom 5.13%Dec 22, 20236 filingsMay 15, 2026SEC
MAZEMaze Therapeutics, Inc.13G/A9.02%3.95M shares+2.11 ppfrom 6.91%Feb 7, 20252 filingsAug 14, 2025SEC
IMUXImmunic, Inc.13G8.69%11.5M shares–Oct 20, 20224 filingsMar 4, 2026SEC
TARSTarsus Pharmaceuticals, Inc.13G/A8.46%3.60M shares+1.35 ppfrom 7.11%Jul 28, 20253 filingsMay 15, 2026SEC
XFORX4 Pharmaceuticals, Inc13G/A8.33%8.04M shares−1.66 ppfrom 9.99%Aug 19, 20252 filingsAug 14, 2026SEC
CNTXContext Therapeutics Inc.13G/A8.27%7.42M shares–May 10, 20242 filingsMay 15, 2025SEC
COAGHemab Therapeutics Holdings, Inc.13G8.15%3.60M sharesNewMay 8, 20261 filingMay 8, 2026SEC
CRMDCorMedix Inc.13G/A7.94%6.27M shares+1.65 ppfrom 6.29%Dec 1, 20252 filingsMay 15, 2026SEC
NRIXNurix Therapeutics, Inc.13G/A7.45%7.74M shares+1.28 ppfrom 6.17%Jun 10, 20229 filingsAug 14, 2026SEC
ATTOAttovia Therapeutics, Inc.13G7.45%3.21M sharesNewAug 12, 20261 filingAug 12, 2026SEC
IPSCCentury Therapeutics, Inc.13G7.34%13.5M sharesNewJan 15, 20261 filingJan 15, 2026SEC
LTGOLatigo Biotherapeutics, Inc.13G7.03%4.45M sharesNewAug 13, 20261 filingAug 13, 2026SEC
ACRSAclaris Therapeutics, Inc.13G7.00%9.35M sharesNewMar 17, 20261 filingMar 17, 2026SEC
AVTXAvalo Therapeutics, Inc.13G/A6.87%3.61M shares+1.06 ppfrom 5.81%Apr 5, 20244 filingsAug 14, 2026SEC
BCAXBicara Therapeutics Inc.13G/A6.21%4.06M shares+1.19 ppfrom 5.02%Feb 12, 20262 filingsMay 15, 2026SEC
ALMSAlumis Inc.13G5.98%7.36M sharesNewApr 7, 20261 filingApr 7, 2026SEC
GPCRStructure Therapeutics Inc.13G/A5.95%12.3M shares−1.37 ppfrom 7.32%Feb 3, 20237 filingsFeb 13, 2026SEC
JTTTJATT III Acquisition Corp13G5.83%450.0K sharesNewSep 2, 20261 filingSep 2, 2026SEC
VERAVera Therapeutics, Inc.13G5.50%3.92M sharesNewMar 11, 20261 filingMar 11, 2026SEC

Showing the 25 largest of 27 stakes.

Latest filings

344 filings on file made by Deep Track Capital, LP or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Deep Track Capital, LP
CompanyFiled (ET)FormStakeChangeEvent dateFiling
JTTTJATT III Acquisition CorpSep 2, 20264:01 PM ET13G5.83%450.0K sharesNewAug 26, 2026SEC
NRIXNurix Therapeutics, Inc.Aug 14, 20268:36 AM ET13G/A7.45%7.74M shares+1.28 ppfrom 6.17%Jun 30, 2026SEC
XFORX4 Pharmaceuticals, IncAug 14, 20268:34 AM ET13G/A8.33%8.04M shares−1.66 ppfrom 9.99%Jun 30, 2026SEC
VRDNViridian Therapeutics, Inc.Aug 14, 20268:32 AM ET13G/A3.25%3.59M shares−2.05 ppfrom 5.30%Below 5%Jun 30, 2026SEC
PSNLPersonalis, Inc.Aug 14, 20268:32 AM ET13G/A3.82%4.00M shares−1.69 ppfrom 5.51%Below 5%Jun 30, 2026SEC
MLTXMoonLake ImmunotherapeuticsAug 14, 20268:28 AM ET13G/A9.74%8.00M shares+3.28 ppfrom 6.46%Jun 30, 2026SEC
MBXMBX Biosciences, Inc.Aug 14, 20268:27 AM ET13G/A3.64%1.73M shares−2.91 ppfrom 6.55%Below 5%Jun 30, 2026SEC
IMVTImmunovant, Inc.Aug 14, 20268:27 AM ET13G/A4.55%9.34M shares−1.04 ppfrom 5.59%Below 5%Jun 30, 2026SEC
ENTAEnanta Pharmaceuticals IncAug 14, 20268:26 AM ET13G/A4.97%1.44M shares−1.81 ppfrom 6.78%Below 5%Jun 30, 2026SEC
ENGNenGene Therapeutics Inc.Aug 14, 20268:25 AM ET13G/A0.00%0 shares−6.69 ppfrom 6.69%Below 5%Jun 30, 2026SEC
AVTXAvalo Therapeutics, Inc.Aug 14, 20268:24 AM ET13G/A6.87%3.61M shares+1.06 ppfrom 5.81%Jun 30, 2026SEC
LTGOLatigo Biotherapeutics, Inc.Aug 13, 20264:05 PM ET13G7.03%4.45M sharesNewAug 7, 2026SEC
ATTOAttovia Therapeutics, Inc.Aug 12, 20264:02 PM ET13G7.45%3.21M sharesNewAug 5, 2026SEC
OBXObsidian Therapeutics, Inc.Aug 11, 20264:03 PM ET13G5.37%3.32M sharesNewAug 4, 2026SEC
STTKShattuck Labs, Inc.Jun 17, 20264:00 PM ET13G5.17%5.00M sharesNewJun 10, 2026SEC
AVTXAvalo Therapeutics, Inc.May 29, 20264:37 PM ET13G5.81%3.06M shares+5.81 ppfrom 0.00%May 22, 2026SEC
DFTXDefinium Therapeutics, Inc.May 15, 20269:14 AM ET13G/A3.01%3.00M shares−2.53 ppfrom 5.54%Below 5%Mar 31, 2026SEC
TARSTarsus Pharmaceuticals, Inc.May 15, 20268:46 AM ET13G/A8.46%3.60M shares+1.35 ppfrom 7.11%Mar 31, 2026SEC
OCULOcular Therapeutix, IncMay 15, 20268:46 AM ET13G/A9.53%20.9M shares+4.40 ppfrom 5.13%Mar 31, 2026SEC
NRIXNurix Therapeutics, Inc.May 15, 20268:45 AM ET13G/A6.17%6.35M shares−1.04 ppfrom 7.21%Mar 31, 2026SEC